121 related articles for article (PubMed ID: 36765481)
1. [Synergistic Antitumor Effect of Everolimus Combined with Gemcitabine on Diffuse Large B-Cell Lymphoma].
Zuo XQ; Tan CL; Li XM; Ma T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):81-88. PubMed ID: 36765481
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.
Dong P; Hao F; Dai S; Tian L
J Recept Signal Transduct Res; 2018 Feb; 38(1):83-88. PubMed ID: 29369007
[TBL] [Abstract][Full Text] [Related]
3. [Effects of mTOR Inhibitor Rapamycin on Burkitt's Lymphoma Cells].
Zhou LH; Zhu XP; Xiao HF; Xin PL; Li CT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1397-1405. PubMed ID: 29070114
[TBL] [Abstract][Full Text] [Related]
4. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
5. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
7. [Effect of MELK Inhibitor OTSSP167 on Diffuse Large B-Cell Lymphoma].
Zhou JY; Huang H; Zhuang Y; Zhong XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):739-745. PubMed ID: 37356934
[TBL] [Abstract][Full Text] [Related]
8. Everolimus reduces postoperative arthrofibrosis in rabbits by inducing autophagy-mediated fibroblast apoptosis by PI3K/Akt/mTOR signaling pathway.
Liu Y; Zhang Z; Yan L; Li X; Zhang J; Zhang X; Zhu D; Sun Y; Jiang Q
Biochem Biophys Res Commun; 2020 Nov; 533(1):1-8. PubMed ID: 32919704
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Xu T; Liu P; Li Q; Shi C; Wang X
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Yang Y; Zhang LJ; Bai XG; Xu HJ; Jin ZL; Ding M
Biomed Pharmacother; 2018 Oct; 106():1307-1316. PubMed ID: 30119201
[TBL] [Abstract][Full Text] [Related]
11. The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Song J; Xu J; Guo J; Shang Y; Wang J; Wang T
Acta Histochem; 2021 Sep; 123(6):151769. PubMed ID: 34416437
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells.
Lin L; Liu X; Yu H; Deng H; Peng K; Chen J; Zhang C; Jiang T; Liu X
Front Pharmacol; 2023; 14():1134895. PubMed ID: 36937854
[No Abstract] [Full Text] [Related]
13. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
[TBL] [Abstract][Full Text] [Related]
14. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
Chen M; Jiang Y; Cai X; Lu X; Chao H
Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
[TBL] [Abstract][Full Text] [Related]
16. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
17. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
[TBL] [Abstract][Full Text] [Related]
18. [Honokiol combined with Gemcitabine synergistically inhibits the proliferation of human Burkitt lymphoma cells and induces their apoptosis].
Zhang MW; Xu XJ; Fan JX; Hung YX; Ye YB; Wang J; Guo KY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):93-8. PubMed ID: 24598658
[TBL] [Abstract][Full Text] [Related]
19. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
[TBL] [Abstract][Full Text] [Related]
20. Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
Li L; Zhao SL; Yue GGL; Wong TP; Pu JX; Sun HD; Fung KP; Leung PC; Han QB; Lau CBS; Leung PS
Phytomedicine; 2018 May; 44():56-64. PubMed ID: 29895493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
